Dublin, Nov. 24, 2022 (GLOBE NEWSWIRE) — The “Global Peptide Therapies Market Size, Share and Trend Analysis Report by Type (Innovative and Generic), by Route of Administration, by Technology Summary, By Manufacturers Type, By Application Report, By Regional Outlook and Forecast, 2022-2028″ has been added to from ResearchAndMarkets.com offer.
The global therapeutic peptides market size is expected to reach USD 58.4 billion by 2028, with the market growing at 6.3% CAGR during the forecast period.
Therapeutic peptides are polypeptides or peptides (oligomers or short polymers of amino acids) that are used to treat disorders. Peptide treatments mimic natural peptide functions such as hormones, neurotransmitters, growth factors, ion channel ligands and anti-infectives. Since peptides can be digested by the body, they are believed to be reasonably safe and well tolerated.
Liraglutide, the most popular diabetes drug on the market, contains a lipid chain that increases plasma circulation and ensures long-term absorption. Liraglutide is a GLP-1 agonist that self-assembles into an alpha-helical structure and should only be consumed once daily. The blood half-life of liraglutide is prolonged to approximately 13-14 hours due to lipid conjugation of a palmitoyl chain to a lysine residue at position 26.
This is attributed to the ability of the palmitoyl chain to bind albumin non-covalently, delaying the proteolytic action of DPP IV and allowing rapid renal clearance. The inclusion of the lipid chain could further extend the half-life by preventing the DPP IV enzyme from sterically degrading.
Lanreotide, an octapeptide, is another peptide that can self-assemble. This drug is a synthetic counterpart of the peptide hormone somatostatin, which is used to relieve acromegaly (a dysfunction where the body produces excessive amounts of growth hormone).
Lanreotide assembles into monodisperse liquid crystalline nanotubes when exposed to water. Nanotubes are composed of dimers that self-assemble into a 2D network that is held together by antiparallel α-sheets and side chain connections. Studies of self-assembled amyloid aggregates created by peptide hormones and neuropeptides have provided insight into how self-assembly, as well as peptide hormones, are related.
COVID-19 Impact Analysis
COVID-19 has been treated using new peptides that have been repurposed as drugs. Researchers around the world are still looking for chemicals that can either stop SARS-CoV-2 infection and replication, or relieve symptoms caused by the virus.
The FDA has revised its definition of a biologic to include chemically produced polypeptides that are more than 40 amino acids in length but less than 100 amino acids (synthetic proteins) and synthetic peptides that are 40 amino acids in length or less (synthetic peptides).
There were 21 peptide drugs in development for the treatment of COVID-19, including 15 synthetic peptides in therapies for the treatment of ARDS and other respiratory disorders caused by SARS-Cov-2 infection.
Market Growth Factors
Growing number of applications
Cardiovascular disease (CVD) remains the leading cause of death and morbidity worldwide. Many interventions are being tested to improve pathological cardiovascular problems, however, few new drugs have been approved for intervention or treatment. Accordingly, new techniques for the treatment of cardiovascular diseases are urgently needed.
Treatment of contributing risk factors and underlying mechanisms, such as inflammation, obesity, high blood sugar and high cholesterol, is frequently used to prevent vascular problems. The pharmaceutical industry has traditionally resisted the use of peptides as therapeutic agents due to their limited stability, size, degradation rate, and poor distribution. However, there has been a renaissance in the development of peptides and their synthetic derivatives for therapeutic intervention in recent years.
Increase in cancer cases worldwide
Cancer is the second leading cause of death, accounting for a considerable number of deaths worldwide in 2013. Cancer rates in developed countries are significantly higher than in developing countries. The prevalence of known risk factors is expected to increase in these underdeveloped countries due to population growth and aging, as well as an increased prevalence of known risk factors.
Lung cancer is the leading cause of cancer death in men worldwide, but only in industrialized countries, while breast cancer is the leading cause of cancer death in developing countries. Mutations in somatic genes that alter the function of the proteins they encode have been linked to cancer. Most solid tumors, such as those of the brain, colon, breast, and pancreas, show somatic changes.
Market restraining factors
Side Effects and Risks of Peptide Therapy
Natural polypeptides like hormones, growth factors and neurotransmitters, unlike synthesized peptide drugs, are considered to play an important role in normal physiology. Membrane impermeability and instability in vivo are two major drawbacks of peptide drugs.
Proteolytic degradation of peptide drugs in serum decreases bioavailable concentration and reduces drug half-life. To maintain the drug at a clinically effective concentration, systematic administration may be necessary. To avoid proteolytic degradation and improve the in vivo half-life of peptide drugs, various chemical modification approaches have been used.
Main topics covered:
Chapter 1. Market Scope and Methodology
Chapter 2. Market Overview
126.96.36.199 Market composition and scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market constraints
Chapter 3. Competitive Analysis – Global
3.1 Cardinal matrix
3.2 Recent Industry-Wide Strategic Developments
3.2.1 Partnerships, collaborations and agreements
3.2.2 Product launches and product extensions
3.2.3 Acquisitions and mergers
3.2.4 Approvals and trails
3.3 Main winning strategies
3.3.1 Percentage Breakdown of Top Leading Strategies (2018-2022)
Chapter 4. Global Peptide Therapies Market by Type
4.1 Global Innovative Market by Region
4.2 Global Generic Market by Region
Chapter 5. Global Market for Therapeutic Peptides by Route of Administration
5.1 Global Parenteral Drugs Market by Region
5.2 Global Pulmonary Market by Region
5.3 Global Mucous membranes Market by Region
5.4 Global Oral Oral Market by Region
5.5 Global Others Market by Region
Chapter 6. Global Peptide Therapies Market by Synthetic Technology
6.1 Global Liquid Phase Peptide Synthesis (LPPS) Market by Region
6.2 Global Solid Phase Peptide Synthesis (SPPS) Market by Region
6.3 Global Hybrid Technology Market by Region
Chapter 7. Global Peptide Therapy Market by Type of Manufacturers
7.1 Global Domestic Market by Region
7.2 Global Outsourcing Market by Region
Chapter 8. Global Peptide Therapies Market by Application
8.1 Global Metabolic Market by Region
8.2 Global Cardiovascular Disorders Market by Region
8.3 Global GIT and Kidney Market by Region
8.4 Global Anti-Infectives and Dermatology Market by Region
8.5 Global Breathing Apparatus Market by Region
8.6 Global Central Nervous System Market by Region
8.7 Global Cancer Market by Region
8.8 Global Pain Management Market by Region
8.9 Global Others Market by Region
Chapter 9. Global Peptide Therapy Market by Region
Chapter 10. Business Profiles
10.1 Eli Lilly and company
10.1.1 Company Overview
10.1.2 Financial analysis
10.1.3 Regional Analysis
10.1.4 Research & Development costs
10.1.5 Strategies and recent developments
10.1.5.1 Partnerships, collaborations and agreements
10.1.5.2 Acquisitions and mergers
10.1.5.3 Approvals and trails
10.2 AstraZeneca PLC
10.2.1 Company Overview
10.2.2 Financial Analysis
10.2.3 Regional Analysis
10.2.4 Research & Development expenses
10.2.5 Strategies and recent developments
10.2.5.1 Partnerships, collaborations and agreements
10.2.5.2 Acquisitions and mergers
10.3 Teva Pharmaceutical Industries Ltd.
10.3.1 Company Overview
10.3.2 Financial analysis
10.3.3 Regional Analysis
10.3.4 Research and development costs
10.3.5 Strategies and recent developments
10.3.5.1 Product Launches and Product Extensions
10.3.5.2 Approvals and Acquisitions
10.4 Novartis AG
10.4.1 Company Overview
10.4.2 Financial analysis
10.4.3 Sectoral and regional analysis
10.4.4 Research and development costs
10.4.5 Recent Strategies and Developments
10.4.5.1 Acquisitions and mergers
10.4.5.2 Approvals and trails
10.5 Pfizer, Inc.
10.5.1 Company Overview
10.5.2 Financial analysis
10.5.3 Regional and Sector Analysis
10.5.4 Research and development costs
10.5.5 Strategies and recent developments
10.5.5.1 Acquisition and merger
10.6 Sanofi SA
10.6.1 Company Overview
10.6.2 Financial analysis
10.6.3 Sectoral and regional analysis
10.6.4 Research and development costs
10.6.5 Strategies and recent developments
10.6.5.1 Partnerships, collaborations and agreements
10.7 GlaxoSmithKline PLC
10.7.1 Company Overview
10.7.2 Financial Analysis
10.7.3 Sectoral and regional analysis
10.7.4 Research and development costs
10.8 Takeda Pharmaceutical Company Limited
10.8.1 Company Overview
10.8.2 Financial Analysis
10.8.3 Regional Analysis
10.8.4 Research and development costs
10.8.5 Strategies and recent developments
10.8.5.1 Partnerships, collaborations and agreements
10.8.5.2 Approvals and Trails
10.9 Lonza Group AG
10.9.1 Company Overview
10.9.2 Financial Analysis
10.9.3 Sectoral and regional analysis
10.9.4 Research and development costs
10.10. Amgen, Inc.
10.10.1 Company Overview
10.10.2 Financial Analysis
10.10.3 Regional Analysis
10.10.4 Research and development costs
10.10.5 Strategies and recent developments
10.10.5.1 Partnerships, collaborations and agreements
For more information about this report visit https://www.researchandmarkets.com/r/66e04f
#Global #Therapeutic #Peptides #Market #Report #Players #include #AstraZeneca #Teva #Pharmaceutical #Industries #Novartis #Pfizer